By Journal Record Staff
Courtesy of The Journal Record
OKLAHOMA CITY – The 2014 BioSummit is scheduled March 26 at the Skirvin Hilton Hotel in Oklahoma City.
Presented by the Oklahoma Bioscience Association, the BioSummit will include experts in scientific discovery, commercialization and funding who will share their insights with scientists and entrepreneurs from across the state.
Topics explored at the BioSummit presented by the Oklahoma Biosciences Association will include funding fundamentals, partners and exit strategies, drug repurposing, positioning for early-stage investments, key elements of marketing and interacting with the bio industry.
“Our researchers and bioscience entrepreneurs will benefit greatly from the experiences of those who have been through the drug discovery and commercialization process before,” said Scott Meacham, president and CEO of i2E Inc., which manages the Oklahoma Bioscience Association.
Speakers will include Scott Meacham, president and CEO, i2E, Inc., William Paiva, managing director of the Oklahoma Life Science Fund; Von Allen, director of development at the University of Oklahoma and the Stephenson Cancer Center; Clayton Duncan, CEO at Accele Biopharma; Doug Branch, director, PhillipsMurrah, Dennis Shafer, president and CEO, Altheus Therapeutics; and William A. Hagstrom president and CEO, Crescendo Bioscience, Elaine Hamm, Director, Proof of Concept Center and Venture Advisor, i2E, Inc. and Vikas Sharma, Director, Business Development, Rexahn Pharmaceuticals & former Manager, Business Development, MedImmune.
Awards to be presented at BioSummit include Hall of Fame Leadership Award, Researcher Recognition Award, Community Recognition Award and Innovation Recognition Award.
For information, visit www.i2E.org or www.okbio.org.
Click here to read the article at the Journal Record website (subscription required).
